By comparing TCR sequences from lung cancer patients treated with ICB therapy with the MAGE-A3 antigen-specific TCRs, we found that the matching TCR clonotypes increased after ICB treatment, and patients with TCR repertoire that were more similar to the candidate TCRs would have better response to ICB therapy. Here, MAGEA3 is linked to lung cancer.